Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...